367 related articles for article (PubMed ID: 33333023)
21. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10.
Ovens MJ; Davies AJ; Wilson MC; Murray CM; Halestrap AP
Biochem J; 2010 Jan; 425(3):523-30. PubMed ID: 19929853
[TBL] [Abstract][Full Text] [Related]
22. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
23. Membrane-anchored carbonic anhydrase IV interacts with monocarboxylate transporters via their chaperones CD147 and GP70.
Forero-Quintero LS; Ames S; Schneider HP; Thyssen A; Boone CD; Andring JT; McKenna R; Casey JR; Deitmer JW; Becker HM
J Biol Chem; 2019 Jan; 294(2):593-607. PubMed ID: 30446621
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia.
Deora AA; Philp N; Hu J; Bok D; Rodriguez-Boulan E
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16245-50. PubMed ID: 16260747
[TBL] [Abstract][Full Text] [Related]
26. Monocarboxylate Transporter 1 in Brain Diseases and Cancers.
Sun Y; Sun J; He Z; Wang G; Wang Y; Zhao D; Wang Z; Luo C; Tian C; Jiang Q
Curr Drug Metab; 2019; 20(11):855-866. PubMed ID: 31631816
[TBL] [Abstract][Full Text] [Related]
27. The monocarboxylate transporter family--Structure and functional characterization.
Halestrap AP
IUBMB Life; 2012 Jan; 64(1):1-9. PubMed ID: 22131303
[TBL] [Abstract][Full Text] [Related]
28. Monocarboxylic acid transport.
Halestrap AP
Compr Physiol; 2013 Oct; 3(4):1611-43. PubMed ID: 24265240
[TBL] [Abstract][Full Text] [Related]
29. Hydrophobic interactions stabilize the basigin-MCT1 complex.
Finch NA; Linser PJ; Ochrietor JD
Protein J; 2009 Oct; 28(7-8):362-8. PubMed ID: 19760495
[TBL] [Abstract][Full Text] [Related]
30. Studies on the DIDS-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle.
Wilson MC; Meredith D; Bunnun C; Sessions RB; Halestrap AP
J Biol Chem; 2009 Jul; 284(30):20011-21. PubMed ID: 19473976
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ.
Wilson MC; Meredith D; Halestrap AP
J Biol Chem; 2002 Feb; 277(5):3666-72. PubMed ID: 11719518
[TBL] [Abstract][Full Text] [Related]
32. Multifunctional Spiky Topological Nanocapsules for the Discrimination and Differential Inhibition of Inflammation and Cancer.
Zhang Y; Li J; Zhang S; Li W; Ouyang J; Na N
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25727-25737. PubMed ID: 34048646
[TBL] [Abstract][Full Text] [Related]
33. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin.
Marchiq I; Le Floch R; Roux D; Simon MP; Pouyssegur J
Cancer Res; 2015 Jan; 75(1):171-80. PubMed ID: 25403912
[TBL] [Abstract][Full Text] [Related]
34. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration.
Beloueche-Babari M; Casals Galobart T; Delgado-Goni T; Wantuch S; Parkes HG; Tandy D; Harker JA; Leach MO
Br J Cancer; 2020 Mar; 122(6):895-903. PubMed ID: 31937921
[TBL] [Abstract][Full Text] [Related]
35. Embigin facilitates monocarboxylate transporter 1 localization to the plasma membrane and transition to a decoupling state.
Xu B; Zhang M; Zhang B; Chi W; Ma X; Zhang W; Dong M; Sheng L; Zhang Y; Jiao W; Shan Y; Chang W; Wang P; Wen S; Pei D; Chen L; Zhang X; Yan H; Ye S
Cell Rep; 2022 Sep; 40(11):111343. PubMed ID: 36103816
[TBL] [Abstract][Full Text] [Related]
36. Glucose-dependent growth arrest of leukemia cells by MCT1 inhibition: Feeding Warburg's sweet tooth and blocking acid export as an anticancer strategy.
Pivovarova AI; MacGregor GG
Biomed Pharmacother; 2018 Feb; 98():173-179. PubMed ID: 29253765
[TBL] [Abstract][Full Text] [Related]
37. In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment.
Benyahia Z; Blackman MCNM; Hamelin L; Zampieri LX; Capeloa T; Bedin ML; Vazeille T; Schakman O; Sonveaux P
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540599
[TBL] [Abstract][Full Text] [Related]
38. CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.
Ames S; Andring JT; McKenna R; Becker HM
Oncogene; 2020 Feb; 39(8):1710-1723. PubMed ID: 31723238
[TBL] [Abstract][Full Text] [Related]
39.
Rodriguez-Cruz V; Morris ME
J Pharmacol Exp Ther; 2021 Jul; 378(1):42-50. PubMed ID: 33963018
[TBL] [Abstract][Full Text] [Related]
40. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
